Partnering with us

Strategic: Create options for the corporation to expand into new therapeutic approaches and businesses

Add value: Help innovators develop their concept from idea to Proof of Concept

Secure financial return to support continuity --> Evergreen Fund Model

Boehringer Ingelheim has built a strong pipeline based on inhouse R&D
Boehringer Ingelheim's pipeline has been complemented via licensing deals and research collaborations
BIVF will create options to expand into new therapeutic approaches and businesses

Immunomodulation, esp. Immuno-Oncology
Tissue Regeneration, e.g. stem cells, NCEs, biologics
New Therapeutic Modalities, e.g. genetherapy, cell-based therapeutics,
ADC
Microbiome

Total fund volume: €100 Mio
Initial investment at an early stage of company's life
Follow-on investments in pace with the company's progress
Staged investments of up to €10 mio over company's lifetime

Strategic orientation: Long-term view
Family owned: Continuity, Cultural Identity
No option required: Openess to join VC syndicates
Successful track record in R&D: Able and willing to provide scientific, managerial and commercial support
Help positioning portfolio companies for an exit

Our Philosophy and Investment Strategy...

Our Philosophy

Why Corporate Venturing?

Our Focus

Fund Volume

Why Boehringer Ingelheim?

Partnering with us